Evelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
August 05 2022 - 6:00AM
Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage
biotechnology company developing a novel platform of orally
delivered medicines acting on the small intestinal axis, SINTAX,
today announced that it will host a conference call and live
webcast at 7:30 a.m. ET on Thursday, August 11, 2022, to report its
second quarter 2022 financial results.
To access the live conference call, please dial (800) 715-9871
(US & Canada) or +44 800 260 6466 (UK) and refer to conference
ID 1143271. A live webcast can be accessed under "News &
Events" in the investors section of Evelo’s
website, https://ir.evelobio.com/news-events. The archived
webcast will be available on Evelo’s website for approximately 90
days following the event.
About Evelo BiosciencesEvelo
Biosciences is a clinical stage biotechnology company
developing a novel platform of orally delivered medicines acting on
the small intestinal axis, SINTAX, with systemic therapeutic
effects. SINTAX plays a central role in governing the immune,
metabolic, and neurological systems. The Company’s product
candidates are pharmaceutical preparations of single strains of
microbes or their extracellular vesicles (EVs). Evelo’s vision is
to create therapies that are effective, safe, well-tolerated, and
affordable to improve the lives of the billions of people living
with inflammatory diseases.
The Company is developing EDP1815, currently in late-stage
development for psoriasis and atopic dermatitis, and EDP2939, about
to enter the clinic to treat inflammatory diseases. Evelo is also
advancing additional product candidates in other disease areas.For
more information, please visit www.evelobio.com and
engage with Evelo on LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements including
within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including statements concerning the
development of EDP1815 and EDP2939, the promise and potential
impact of our product candidates, the timing of and plans for
clinical trials, and the timing and results of clinical trial
readouts.
These forward-looking statements are based on management's
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the
following: the impact of the COVID-19 pandemic on our operations,
including our preclinical studies and clinical trials, and the
continuity of our business; we have incurred significant losses,
are not currently profitable and may never become profitable; our
need for additional funding; our limited operating history; our
unproven approach to therapeutic intervention; the lengthy,
expensive, and uncertain process of clinical drug development,
including potential delays in regulatory approval; our reliance on
third parties and collaborators to expand our microbial library,
conduct our clinical trials, manufacture our product candidates,
and develop and commercialize our product candidates, if approved;
our lack of experience in manufacturing, selling, marketing, and
distributing our product candidates; failure to compete
successfully against other drug companies; protection of our
proprietary technology and the confidentiality of our trade
secrets; potential lawsuits for, or claims of, infringement of
third-party intellectual property or challenges to the ownership of
our intellectual property; our patents being found invalid or
unenforceable; risks associated with international operations; our
ability to retain key personnel and to manage our growth; the
potential volatility of our common stock; our management and
principal stockholders have the ability to control or significantly
influence our business; costs and resources of operating as a
public company; unfavorable or no analyst research or reports; and
securities class action litigation against us.
These and other important factors discussed under the caption
"Risk Factors" in our Quarterly Report on Form 10-Q for the
three-month period ended June 30, 2022, and our other reports filed
with the SEC, could cause actual results to differ materially from
those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent
management's estimates as of the date of this press release. While
we may elect to update such forward-looking statements at some
point in the future, except as required by law, we disclaim any
obligation to do so, even if subsequent events cause our views to
change. These forward-looking statements should not be relied upon
as representing our views as of any date subsequent to the date of
this press release.
Contacts
Investors:Kendra Sweeney,
239-877-7474ksweeney@evelobio.com
Media:Jessica Cotrone,
978-760-5622jcotrone@evelobio.com
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Apr 2023 to Apr 2024